Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 168

1.

Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS.

Gheuens S, Smith DR, Wang X, Alsop DC, Lenkinski RE, Koralnik IJ.

Neurology. 2012 May 1;78(18):1390-3. doi: 10.1212/WNL.0b013e318253d61e. Epub 2012 Apr 18.

2.

Immune-reconstitution Inflammatory Syndrome in Multiple Sclerosis Patients Treated With Natalizumab: A Series of 4 Cases.

N'gbo N'gbo Ikazabo R, Mostosi C, Quivron B, Delberghe X, El Hafsi K, Lysandropoulos AP.

Clin Ther. 2016 Mar;38(3):670-5. doi: 10.1016/j.clinthera.2016.01.010. Epub 2016 Feb 5.

PMID:
26856928
3.

Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS.

Marousi S, Travasarou M, Karageorgiou CE, Gheuens S, Koralnik IJ.

Neurology. 2012 Nov 20;79(21):2160; author reply 2160. doi: 10.1212/01.wnl.0000423208.11698.16. No abstract available.

PMID:
23170016
4.

Punctate lesion pattern suggestive of perivascular inflammation in acute natalizumab-associated progressive multifocal leukoencephalopathy: productive JC virus infection or preclinical PML-IRIS manifestation?

Wattjes MP, Verhoeff L, Zentjens W, Killestein J, van Munster ET, Barkhof F, van Eijk JJ.

J Neurol Neurosurg Psychiatry. 2013 Oct;84(10):1176-7. doi: 10.1136/jnnp-2013-304986. Epub 2013 May 21. No abstract available.

PMID:
23695498
5.

Immune reconstitution inflammatory syndrome in natalizumab-associated PML.

Tan IL, McArthur JC, Clifford DB, Major EO, Nath A.

Neurology. 2011 Sep 13;77(11):1061-7. doi: 10.1212/WNL.0b013e31822e55e7. Epub 2011 Aug 10.

6.

Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy.

Metz I, Radue EW, Oterino A, Kümpfel T, Wiendl H, Schippling S, Kuhle J, Sahraian MA, Gray F, Jakl V, Häusler D, Brück W.

Acta Neuropathol. 2012 Feb;123(2):235-45. doi: 10.1007/s00401-011-0900-5. Epub 2011 Nov 6.

7.

Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumab.

Kleinschmidt-DeMasters BK, Miravalle A, Schowinsky J, Corboy J, Vollmer T.

J Neuropathol Exp Neurol. 2012 Jul;71(7):604-17. doi: 10.1097/NEN.0b013e31825caf2c. Review.

PMID:
22710964
8.

Minimal supportive treatment in natalizumab-related PML in a MS patient.

Lalive PH, Bridel C, Ferfoglia RI, Kaiser L, Du Pasquier R, Barkhof F, Haller S.

J Neurol Neurosurg Psychiatry. 2015 Mar;86(3):354-5. doi: 10.1136/jnnp-2014-308154. Epub 2014 Jun 23. No abstract available.

PMID:
24957322
9.

Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients.

Dahlhaus S, Hoepner R, Chan A, Kleiter I, Adams O, Lukas C, Hellwig K, Gold R.

J Neurol Neurosurg Psychiatry. 2013 Oct;84(10):1068-74. doi: 10.1136/jnnp-2013-304897. Epub 2013 Apr 19.

10.

The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy.

Wattjes MP, Richert ND, Killestein J, de Vos M, Sanchez E, Snaebjornsson P, Cadavid D, Barkhof F.

Mult Scler. 2013 Dec;19(14):1826-40. doi: 10.1177/1352458513510224. Epub 2013 Nov 5. Review.

PMID:
24192217
11.

Natalizumab-associated progressive multifocal leukoencephalopathy in a patient with multiple sclerosis: a postmortem study.

Wüthrich C, Popescu BF, Gheuens S, Marvi M, Ziman R, Denq SP, Tham M, Norton E, Parisi JE, Dang X, Lucchinetti CF, Koralnik IJ.

J Neuropathol Exp Neurol. 2013 Nov;72(11):1043-51. doi: 10.1097/NEN.0000000000000005.

12.

MRI characteristics of early PML-IRIS after natalizumab treatment in patients with MS.

Wattjes MP, Wijburg MT, Vennegoor A, Witte BI, de Vos M, Richert ND, Uitdehaag BM, Barkhof F, Killestein J; Dutch-Belgian Natalizumab-associated PML study group.

J Neurol Neurosurg Psychiatry. 2016 Aug;87(8):879-84. doi: 10.1136/jnnp-2015-311411. Epub 2015 Sep 14.

13.

Clinically silent PML and prolonged immune reconstitution inflammatory syndrome in a patient with multiple sclerosis treated with natalizumab.

Blinkenberg M, Sellebjerg F, Leffers AM, Madsen CG, Sørensen PS.

Mult Scler. 2013 Aug;19(9):1226-9. doi: 10.1177/1352458513481010. Epub 2013 Mar 18.

PMID:
23508652
14.

Natalizumab affects the T-cell receptor repertoire in patients with multiple sclerosis.

Warnke C, Mausberg AK, Stettner M, Dehmel T, Nekrich L, Meyer zu Horste G, Hartung HP, Fogdell-Hahn A, Adams O, Kieseier BC.

Neurology. 2013 Oct 15;81(16):1400-8. doi: 10.1212/WNL.0b013e3182a84101. Epub 2013 Sep 18.

PMID:
24049136
15.

Multiple sclerosis update: use of MRI for early diagnosis, disease monitoring and assessment of treatment related complications.

Igra MS, Paling D, Wattjes MP, Connolly DJA, Hoggard N.

Br J Radiol. 2017 Jun;90(1074):20160721. doi: 10.1259/bjr.20160721. Epub 2017 Apr 26. Review.

PMID:
28362522
16.

Surgical management of malignant cerebral edema secondary to immune reconstitution inflammatory syndrome from natalizumab-associated progressive multifocal encephalopathy.

Tan LA, Lopes DK.

J Clin Neurosci. 2015 Oct;22(10):1669-71. doi: 10.1016/j.jocn.2015.05.003. Epub 2015 Jun 24. Review.

PMID:
26115897
17.

JCV GCN in a natalizumab-treated MS patient is associated with mutations of the VP1 capsid gene.

Agnihotri SP, Dang X, Carter JL, Fife TD, Bord E, Batson S, Koralnik IJ.

Neurology. 2014 Aug 19;83(8):727-32. doi: 10.1212/WNL.0000000000000713. Epub 2014 Jul 18.

18.

Presumptive progressive multifocal leukoencephalopathy in multiple sclerosis after natalizumab therapy.

Eisele P, Szabo K, Hornberger E, Griebe M, Hennerici MG, Kieseier BC, Gass A.

J Neuroimaging. 2014 Jul-Aug;24(4):425-8. doi: 10.1111/jon.12010. Epub 2013 Jan 16.

PMID:
23323645
19.

Risk of natalizumab-associated progressive multifocal leukoencephalopathy.

Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, Lee S, Plavina T, Scanlon JV, Sandrock A, Bozic C.

N Engl J Med. 2012 May 17;366(20):1870-80. doi: 10.1056/NEJMoa1107829.

20.

Progressive multifocal leukoencephalopathy after natalizumab discontinuation.

Fine AJ, Sorbello A, Kortepeter C, Scarazzini L.

Ann Neurol. 2014 Jan;75(1):108-15. doi: 10.1002/ana.24051.

PMID:
24242357

Supplemental Content

Support Center